DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Saturday morning. The firm issued a hold rating on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Wednesday, February 21st.

DBV Technologies Stock Up 6.7 %

DBV Technologies stock opened at $0.71 on Friday. The business has a 50-day simple moving average of $0.78 and a two-hundred day simple moving average of $0.87. The company has a market cap of $136.07 million, a P/E ratio of -1.81 and a beta of 0.75. DBV Technologies has a 52-week low of $0.65 and a 52-week high of $2.37.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.10. The business had revenue of $8.88 million during the quarter, compared to the consensus estimate of $1.10 million. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. During the same period in the previous year, the company posted ($0.23) EPS. Research analysts anticipate that DBV Technologies will post -0.88 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

Several institutional investors have recently made changes to their positions in the business. Optiver Holding B.V. grew its position in shares of DBV Technologies by 595.2% during the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after purchasing an additional 235,337 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new position in DBV Technologies during the 3rd quarter valued at approximately $94,000. Finally, Cowen AND Company LLC purchased a new position in DBV Technologies during the 4th quarter valued at approximately $49,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.